跳至主要内容
临床试验/DRKS00025692
DRKS00025692已完成未知

Assessment of the nasal residence time of AM-301 nasal spray - AM-301-CL-20-03

Altamira Medica AG0 个研究点目标入组 12 人开始时间: 2021年7月5日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 50 Years(—)
性别
Male

入选标准

  • Healthy, non-smoking male, with age from 18-50 years.
  • Body Mass Index (BMI) of 18.0-25.0 kg/m2;

排除标准

  • Main exclusion criteria:
  • Any clinically relevant nasal obstruction or pathology precluding effective and/or efficient intranasal delivery (controlled by endoscopy of the nasal cavity).
  • Any treatment with nasal treatments within 30 days prior to the assessment visit (including nasal spays, nasal drops and saline washes).
  • Any clinically relevant medical history or concomitant medication, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject’s ability to participate in the study.

研究者

发起方
Altamira Medica AG

相似试验